← All trials
NCT05152355
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2019
- Primary completion
- May 9, 2021
- Completion date
- May 9, 2021
- First posted
- Dec 9, 2021
- Last posted
- Dec 9, 2021
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Intech Biopharm Ltd.Lead sponsor
- Intech Biopharm Ltd.Study chair
- Peking UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Hebei UniversityCollaborator
- Jinan UniversityCollaborator
- Inner Mongolia Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Shaanxi Provincial People's HospitalCollaborator
- Qingdao Municipal HospitalCollaborator
- Daqing Oil Field HospitalCollaborator
- Meizhou City Hospital Of Guangdong ProvienceCollaborator
- Bao Gang HospitalCollaborator
- Government of ChinaCollaborator
- Beijing Yi Hua Hospital Management Co., LtdCollaborator
- GCP-Service International Ltd. & Co. KGCollaborator
- National Key Technologies R&D Program for the 12th Five-year PlanCollaborator
- Meihekou Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.